Oncology News | pharmaphorum

News

Views & Analysis

The Frauenkirche is a church in the Bavarian city of Munich that serves as the cathedral of the Archdiocese of Munich and Freising and seat of its Archbishop.

ESMO round-up: Big win for AstraZeneca in ovarian cancer, an...

Several drugmakers announced significant trial findings at this week’s European Society for Medical Oncology (ESMO) conference in Munich.

News

Chronic lymphocytic leukemia (CLL) is a type of cancer of the blood and bone marrow - the spongy tissue inside bones where blood cells are made.

AbbVie's CLL drug Venclyxto too expensive for NHS, says NICE

NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche's MabThera/Rituxan (rituximab), is not a cost-effective use of NHS resources as a treatment for

News

Innate Pharma gains rights to AZ's recently approved leukaem...

France’s Innate Pharma has gained rights to AstraZeneca's recently approved leukaemia drug Lumoxiti, in a deal that expands a collaboration that began more than three years ago.

News

Bayer plans filings for prostate cancer drug darolutamide

Bayer is planning regulatory filings of darolutamide in prostate cancer following phase III trial results showing it helped prevent the disease from spreading, in a niche where Pfizer and J

News

AZ/Merck & Co's Lynparza scores huge ovarian cancer win

AstraZeneca and Merck & Co’s Lynparza (olaparib) has massively reduced the risk of BRCA-mutated ovarian cancer progressing in patients who have just been treated with chemo, in trial re

News

Roche's Tecentriq posts trial wins in two key indications

Roche has scored two big wins with its Tecentriq cancer immunotherapy at ESMO in tough to treat triple negative breast cancer, and untreated lung cancer, as the company plays catch-up with

ESMO round-up: Big win for AstraZeneca in ovarian cancer, an...

AbbVie's CLL drug Venclyxto too expensive for NHS, says NICE

Innate Pharma gains rights to AZ's recently approved leukaem...

Bayer plans filings for prostate cancer drug darolutamide

AZ/Merck & Co's Lynparza scores huge ovarian cancer win

Roche's Tecentriq posts trial wins in two key indications

Curium strikes $8bn deal to buy radiopharma rival Lantheus

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks